Introduction
Traditional mood stabilizers such as valproate, lithium, lamotrigine, and carbamazepine are essential for treating bipolar disorder. Carbamazepine is an anticonvulsant that lowers nerve impulses responsible for pain and seizures. Lamotrigine acts by modulating voltage-gated ion channels and stabilizing neuronal membranes, while Lithium down-regulates and up-regulates specific genes in neurons. Valproate products increase gamma-aminobutyric acid (GABA) action and obstruct voltage-gated sodium channels. This work discusses mood stabilizers by mechanism of action, baseline assessment, laboratory considerations, special populations, FDA-approved indications, dosing, drug-drug interactions, and the social, legal, and ethical implications of prescribing these medications.
Carbamazepine
Mechanism of Action
Carbamazepine modulates voltage-gated sodium channels (VGSCs), leading to reduced synaptic transmission and inhibition of action potentials. Carbamazepine connects with the alpha subunit of the VGSC, especially at the binding pocket established by the peripheral pore loop as well as the pore-lining part of its domain IV (Maan et al., 2023). The drug maintains sodium channels in an inactivated state, reducing the number of channels that open and blocking the formation of action potentials.
Baseline Assessment and Laboratory Considerations
The liver metabolizes carbamazepine to an active metabolite, carbamazepine-10,11-epoxide, which is the main product responsible for its pharmacological action. It is critical to screen for HLA-B*1502 and HLA-A*3101 genotypes, along with a pregnancy test, in women (Maan et al., 2023). Laboratory evaluation should include complete blood counts, liver function tests (LDH, SGPT, SGOT, alkaline phosphatase, and bilirubin), kidney function tests, and serum electrolyte levels, especially in older people who are at risk of hyponatremia.
Special Population Considerations
Carbamazepine shows different responses and effects across diverse populations, depending on age and assigned gender at birth. Carbamazepine causes hyponatremia in about 6-31 percent of patients, which is infrequent in children but highly likely among the elderly population who may develop the condition many months following the start of the medication (American Psychiatric Association [APA], 2010). Moreover, women using oral contraceptives are discouraged from using the drug.
FDA Approval Indications
Carbamazepine FDA approval indications encompass acute manic and mixed occurrences of bipolar disorder. A systematic review indicates the efficacy of the carbamazepine prolonged release in bipolar I mania among patients having mixed or manic episodes (Maan et al., 2023). It is also utilized off-label in maintaining treatment for bipolar disorder. In a cross-sectional study of carbamazepine, valproic acid, and lithium, patients using carbamazepine have a greater risk of relapse.
Dosing
Patients aged 12 years and above should take daily doses between 200 and 600mg, divided into three to four doses. Inhospitalized patients having acute mania, the dose might increase by 200 mg until between 800 and 1000mg, except if side effects occur (APA, 2010). In less acutely ill patients, dosage adjustments should be slower, as rapid increases may trigger vomiting, nausea, or mild neurological symptoms.
Drug-Drug Interaction
Patients treated with carbamazepine are advised not to use grapefruit juice since it acts to elevate blood concentrations of the drug. Grapefruit juice is known to inhibit the action of cytochrome P450; ingesting it increases the bioavailability of carbamazepine (Tayutivutikul et al., 2022). Moreover, similar studies by García et al. (2021) showed that carbamazepine has a long plasma half-life of about 34-38 hours. Carbamazepine induces cytochrome P450 enzymes and can enhance lurasidone metabolism, potentially affecting safety and tolerability (Chiu et al., 2014). Lurasidone can also inhibit its own metabolism, increasing its plasma levels when given with carbamazepine.
Lamotrigine
Mechanism of Action
Lamotrigine acts by regulating voltage-gated ion channels, especially those that inhibit neuronal excitability. They also have neuroprotective impacts, possibly by inhibiting glutamate release and enhancing GABAergic neurotransmission (Costa & Vale, 2023). The comparison of lamotrigine’s exceptional mechanism of action has resulted in investigating its use in managing other central nervous system disorders, such as post-traumatic stress disorder, neuropathic pain, and major depressive disorder.
Baseline Assessment and Laboratory Considerations
The baseline monitoring values for lamotrigine remain unestablished to date due to its pharmacokinetics with other drugs, the effects of these drugs on its serum concentrations, and clinical decisions during concomitant use. Laboratory assessment should include serum levels of concurrent bipolar drugs, kidney function tests, and liver function tests (Betchel et al., 2023). The assessments help monitor patient response to treatment and the risks involved in drug metabolism.
Special Population Considerations
A search and review of the literature reveals no specific research focused on the impact of lamotrigine on gender. However, pharmacokinetics could be influenced by variations in hormone levels and metabolism. Lamotrigine is used by people of all ages, including children, adults, and older people. For bipolar disorder, the dosage may be adjusted between 200 mg and 400 mg based on age, with further consideration given to other drugs issued concurrently with it.
FDA Approval Indications
Lamotrigine is used in treating type 1 bipolar disorder, rapid-cycling bipolar depression, panic disorder, and the management of basilar migraine characterized by aura. The drug is also used as an anti-epilepsy or anti-seizure, which was first approved in 1994 in the U.S. (Betchel et al., 2023). It is regarded as a first-line drug for treating tonic-clonic seizures. This encompasses complex and simple seizures as well as Lennox-Gastaut syndrome.
Dosing
Lamotrigine is available as tablets, orally disintegrating tablets, chewable tablets, and other formulations. Its dosage needs alteration if administered concurrently with other medications such as carbamazepine, valproic acid, lopinavir, and rifampin. The drug should be administered between 200mg and 400mg, with further consideration placed when other medications are taken concurrently (Betchel et al., 2023). In cases of renal or hepatic impairment, the dosage should be reduced.
Drug-Drug Interaction
Concurrent administration of lamotrigine with valproate results in a pharmacokinetic interaction, leading to increased lamotrigine levels in the blood. To lower the risk of developing the rash, especially in patients administered with valproate, the dose is reduced from 25mg to 12.5mg (Betchel et al., 2023). Lamotrigine dosing requires adjustment if given concurrently with rifampin, as rifampin increases its metabolism, hence the need for close monitoring.
Lithium
Mechanism of Action
Unlike other bipolar medications, lithium’s precise mechanism of action remains unclear. The drug addresses bipolar disorder by down-regulating and up-regulating precise genes within neurons (Gao & Calabrese, 2021). Lithium alters the regulation of sodium transport in muscle and nerve cells, and it affects neurotransmitters involved in metabolism, especially serotonin and catecholamines (Drugs.com, n.d.).Lithium also alters intracellular signaling through second messenger systems by inhibiting inositol monophosphatase.
Baseline Assessment and Laboratory Considerations
Baseline assessments include performing thyroid and renal function tests to assess the kidneys’ and thyroid’s ability to handle the drug. For patients aged 50 years and above, electrocardiograms should be performed once or twice a year to assess the drug’s impact on cardiac function (Chokhawala et al., 2024). Laboratory monitoring entails determining trough plasma levels after a lithium dose.
Special Population Considerations
Patients with renal impairments should have a reduced dosage to ensure no lithium toxicity in the blood. If creatinine clearance is less than 30 mL/min, lithium is not recommended (Chokhawala et al., 2024). Pregnancy considerations are essential since using lithium in the first trimester increases the possibility of cardiac malformations. Older patients should not use lithium concurrently with angiotensin receptor blockers, ACE inhibitors, or loop diuretics since it can result in the potential danger of toxicity.
FDA Approval Indications
Lithium is a mood stabilizer marked as mono-therapy for treating bipolar I disorder. Treatment is administered to patients with mixed and acute episodes, especially at 7 years and above (Chokhawala et al., 2024). Lithium is off-label for managing major depressive disorders in the form of adjunct therapy, alleviating neutropenia, managing vascular headaches, and addressing bipolar disorder with no mania. Lithium is a mood stabilizer agent and continues to be used as an ideal first-line medication.
Dosing
Lithium is administered orally in liquid, capsule, or pill form. In adults, lithium requires 1-3 weeks to exert its effects, leading to remission and symptom alleviation (Chokhawala et al., 2024). The response is insufficient; it is recommended to consider plasma lead assessment and adjust the dose accordingly. Stabilized patients might require a single nighttime dose to address adverse effects.
Drug-Drug Interaction
Concomitant administration of lisinopril and lithium may cause lithium levels in the blood to increase substantially, leading to lithium intoxication. The interaction can cause serious effects on elderly persons or individuals with congestive heart failure, kidney impairment, or dehydration (Lithium, n.d.).Moreover, concurrent use of furosemide heightens lithium’s effects. Symptoms such as vomiting, tremor, increased urination, and muscle weakness may be noted.
Valproate
Mechanism of Action
Valproate lowers neuronal hyper-excitability by firming GABAergic transmission and blocking sodium and calcium ion passages. Bourin (2020) states that valproate inhibits or activates intended targets through precise channels or unidentified mechanisms. Valproate enhances GABA synthesis by accelerating the activity and expression of glutamic acid decarboxylase, which converts glutamate (Rahman et al., 2023). The process also increases GABA activity and levels in the body.
Baseline Assessment and Laboratory Considerations
Liver function tests should be included in baseline assessments and repeated 6 months after valproate treatment. Complete blood count, coupled with coagulation tests and serum ammonia levels, was assessed at baseline and repeated periodically. Moreover, serum valproate levels should be recorded between 50 and 125 mcg/mL for the treatment of mania (Rahman et al., 2023). In a hypoalbuminemic condition, valproate assessment is essential due to its protein-binding properties. The drugs can cause liver toxicity if not well-monitored.
Special Population Considerations
Patients with moderate or mild hepatic impairment should reduce the dosage by 50% (Rahman et al., 2023). Pregnancy considerations are essential since valproate can cross the placental barrier and reach fetal circulation, causing teratogenic effects and increased risks of congenital malformations (Rahman et al., 2023). Elderly patients might encounter increased risks of valproate following susceptibility to hepatotoxicity. Children should have reduced dosage and adjusted until seizure control is attained.
FDA Approval Indications
FDA-approved valproate is used for treating and managing psychomotor seizures (complex partial seizures). Divalproex sodium is a stable, well-coordinated valproate derivative. It is used to address numerous seizure disorders such as absence epilepsy, status epileptic-us, generalized convulsions, partial seizures, and myoclonic epilepsy disorders (Rahman et al., 2023). Valproate manages acute depressive episodes seen in bipolar disorder as well as mixed and severe manic episodes.
Dosing
Valproate is administered orally as tablets, capsules, or sprinkles or intravenously. Valproate can be given as an adjunctive or mono-therapy in patients. The initial dosage ranges between 10 and 15 mg/kg/d (Rahman et al., 2023). This can be reviewed and increased accordingly depending on the patient’s response to treatment. Treatment of mania can start with a dose between 250 and 500 mg/kg every day and is reviewed accordingly.
Drug-Drug Interaction
The concurrent use of valproate with amitriptyline can result in adverse effects among patients. The combination of the two drugs can lead to uneven heartbeat, dizziness, blurred vision, extreme drowsiness, and seizures (Drug interactions between amitriptyline and valproate sodium, n.d.). However, it is advisable to consult with the doctor for further medication advice. Contrarily, a recent body of research has not established adverse effects between estrogen-containing birth control and valproate medication.
Ethical, Legal, and Social Implications Related to Prescribing Bipolar Medications
Ethically, it is essential to weigh the benefits, possible side effects, and risks when prescribing bipolar medication. Moreover, it is essential to exercise and respect patient autonomy when considering administering bipolar drugs. From a legal perspective, it is essential to comply with established prescribing policies and to evaluate potential adverse drug effects to avoid immediate litigation from malpractice claims. In addition, stigma relating to bipolar conditions may influence the readiness of a patient to seek treatment, hence the need to focus on mental health awareness and systematization campaigns to increase access to required care.
Conclusion
The traditional four mood stabilizers, including lithium, valproate, carbamazepine, and lamotrigine, are essential in managing bipolar disorder. Their diverse mechanisms of action, including regulation of neurotransmitter signaling, intracellular processes, and ion channels, contribute to their mood-stabilizing effects. Despite widespread use, every medication has specific administration requirements. It is also essential to consider the potential impacts of drug-drug interactions when these medications are taken concurrently with other drugs.
References
American Psychiatric Association. (2010). Practice guidelines for the treatment of patients with bipolar disorder (2nd ed.).
Appel, J. M. (2023). Ethical and legal aspects of treating bipolar disorder. Psychiatry Online, 21(4), 394-398.
Betchel, N. T., Fariba, K. A., & Saadabadi, A. (2023). Lamotrigine. StatPearls.
Bourin, M. (2020). Mechanism of action of valproic acid and its derivatives. Symbiosis Online Journal of PharmaceuticalSciences, 7(1), 1-4.
Chiu, Y. Y., Ereshefsky, L., Preskorn, S. H., Poola, N., & Loebel, A. (2014). Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabolism and Drug Interactions, 29(3), 191-202.
Chokhawala, K., Lee, S., & Saadabadi, A. (2024). Lithium. StatPearls.
Costa, B., & Vale, N. (2023). Understanding lamotrigine’s role in the CNS and possible future evolution. International Journal of Molecular Sciences, 24(7).
Drug interactions between amitriptyline and valproate sodium. (n.d.). Drug.com.
Lithium. (n.d.). Drug.com.
Goldin, D. S. (2023). Fast facts for psychopharmacology for nurse practitioners. Springer Publishing Company.
Maan, J. S., Duong, T. H., & Saadabadi, A. (2023). Carbamazepine. StatPearls.
Rahman, M., Awosika, A. O., & Nguyen, H. (2023). Valproic acid. StatPearls.
Tayutivutikul, N., Wanleenuwat, P., Panapongvasin, T., Klajing, R., & Iwanowski, P. (2022). Dietary effects on antiseizure drug metabolism and management of epilepsy. Seizure, 102(1), 14-21.